News

One year of treatment with Cosentyx (secukinumab) showed safety and efficacy in a real-world study conducted in Italy, lowering disease activity among people with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Men were overall more likely than women to achieve disease remission after a year of treatment. “This…

People with ankylosing spondylitis (AS) are at a significantly higher risk of stroke — a 56% greater risk — than those without this disease, according to a pooled analysis of 11 published studies involving more than 1.7 million participants. Management of stroke risk factors and control of systemic (bodywide)…

Machine learning methods may help in the early detection of ankylosing spondylitis (AS), a new study reported. “It’s fantastic to see the cutting-edge role that machine learning can play in the early identification of patients with health conditions such as AS … Though it is in its early stages,…

When combined with modern evidence-based medicine, treatment with the traditional Chinese herbal medicine Duhuo Jisheng decoction may help relieve pain and improve mobility in people with ankylosing spondylitis (AS), according to an analysis of clinical trial data. “Current evidence suggests that [Duhuo Jisheng decoction] combined with Western medicine is…

A high concentration formulation of Sandoz’s biosimilar Hyrimoz (adalimumab-adaz) has been approved by the U.S. Food and Drug Administration (FDA) to treat ankylosing spondylitis (AS) and other conditions. The new citrate-free formulation (100 mg/mL) is expected to be available on July 1, according to Sandoz. It’s approved for seven…

Low levels of the protein DUSP22 in certain immune cells may contribute to more severe ankylosing spondylitis (AS), according to a new study. The findings suggest that measuring DUSP22 levels could be useful as a way to assess disease activity and responses to treatments, the researchers said, noting…

A new study has identified more than a dozen medications that may serve as treatments for osteoporosis in people with ankylosing spondylitis (AS). The medications target genes common to both osteoporosis and AS, but more studies will be needed to determine whether they can ease AS-associated osteoporosis. The study,…

People with ankylosing spondylitis (AS) are more likely to develop osteoporosis than the general population, and also seem to develop it earlier in life, according to data from a large medical database in Israel. The risk of the bone condition was particularly higher for women, older patients, and people…

The approved therapy Taltz (ixekizumab) can effectively ease symptoms of ankylosing spondylitis and related forms of arthritis that affect the spine, a new analysis shows. The study, “The Efficacy and Safety of Subcutaneous Ixekizumab for the Treatment of Axial Spondylarthritis: A Systematic Review and Meta-Analysis,”…

Adults with ankylosing spondylitis and other forms of arthritis are significantly less likely to be employed than people without arthritis, according to a new analysis from the U.K. Results suggest the effect of arthritis on employment is especially pronounced in certain demographic groups, particularly women and people without college…